1. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408). (23rd June 2022) Authors: Loges, S.; Heuser, M.; Chromik, J.; Sutamtewagul, G.; Kapp-Schwoerer, S.; Crugnola, M.; Di Renzo, N.; Lemoli, R.; Mattei, D.; Ben-Batalla, I.; Waizenegger, J.; Rieckmann, L.-M.; Janning, M.; Imbusch, C. D.; Beumer, N.; Micklem, D.; Gorcea-Carson, C.; Lawson, G.; Nautiyal, J.; Deharo, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗